KRAS and colorectal cancer: Previous studies of ctDNA in colorectal cancer patients have demonstrated a positive selection of mutant KRAS clones during epidermal growth factor receptor (EGFR) blockade10,13, and a decline in mutant KRAS clones upon the withdrawal of the therapy9.